Surgical Treatment of Distal Cholangiocarcinoma

Curr Oncol. 2022 Sep 17;29(9):6674-6687. doi: 10.3390/curroncol29090524.

Abstract

Distal cholangiocarcinoma (dCCA) is a rare malignancy arising from the epithelial cells of the distal biliary tract and has a poor prognosis. dCCA is often clinically silent and patients commonly present with locally advanced and/or distant disease. For patients identified with early stage, resectable disease, surgical resection with negative margins remains the only curative treatment strategy available. However, despite appropriate treatment and diligent surveillance, risk of recurrence remains high with nearly 50% of patients experiencing recurrence at 5 years subsequent to surgical resection; therefore, it is prudent to continue to optimize neoadjuvant and adjuvant therapies in order to reduce the risk of recurrence and improve overall survival. In this review, we discuss the clinical presentation, workup and surgical treatment of dCCA.

Keywords: distal cholangiocarincoma; hepatobiliary; malignancy.

Publication types

  • Review

MeSH terms

  • Bile Duct Neoplasms* / surgery
  • Bile Ducts, Intrahepatic / pathology
  • Cholangiocarcinoma* / pathology
  • Cholangiocarcinoma* / surgery
  • Combined Modality Therapy
  • Humans
  • Neoadjuvant Therapy

Grants and funding

This research received no external funding.